TargetSeq® HBV Panel is designed for HBV typing, HBV mutation detection and HBV-host genomic integration site analysis It is suitable for HBV-related cancer research.
Panel Number | T2015XV1 |
Technical Platform | TargetSeq® Hybridization Capture Sequencing |
Coverage Size | 17.6 Mb |
Reference Database | NCBI/Taxonomy |
Reference Genome | 5,500 full-length seqeunces of 8 types of HBV |
Coverage | HBV genome full length |
Storage | -20℃±5℃ |
Sequence Platform | Illumina / MGI |
Recommend Sequencing Read Length | PE150 |
Recommend Sequencing Data Size and Depth | 1 Gb |
Panel designed based on the full length of 5500 HBV genome sequences of 8 subtypes.
Compatible with various sample types such as tissue, cells, and plasma.
Compatible with both Illumina and MGI sequencing platforms.
The oncogenic effects of preS combination mutations have rarely been studied compared to HBV preS deletions. Using a prospective cohort study including 2114 subjects, the authors found that the preS combination mutations G2950A/G2951A/A2962G/C2964A and C3116T/T31C significantly increased the risk of HCC in patients not receiving antiviral therapy, whereas preS2 deletions significantly increased the risk of HCC in patients receiving antiviral therapy.
| Product Name | Panel Number | Set | Cat. No |
| TargetSeq® HBV Panel | T2015XV1 | 16 rxn | PH2001301 |
| 96 rxn | PH2001302 |
CN
